EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Extracorporeal photopheresis for refractory BK virus–associated nephropathy in kidney transplantation

Víctor J Escudero-Saiz iD, Marc Xipell iD, Ángela González iD, Diana Rodríguez-Espinosa iD, Judit Cacho, Carolt Arana iD, Gastón J Piñeiro, Pedro Ventura-Aguiar iD, Jordi Rovira iD, Ana B Larque, Paola Charry, Joan Cid iD und 4 weitere

Clinical Kidney Journal · 01.12.2025 · 18 (12)

DOI: 10.1093/ckj/sfaf250 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 07.08.2025. Verfasst von Víctor J Escudero-Saiz und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology and Kidney Transplantation, Hospital Clínic Barcelona, Catalonia, Spain. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

BK virus–associated nephropathy (BKVAN) remains an important risk factor for kidney graft loss. The current strategy to treat the BKVAN consists in reducing immunosuppressants. However, this strategy increases the risk of graft rejection, especially in highly sensitized patients or those with previous rejection episodes. Extracorporeal photopheresis (ECP) has been used for the treatment of T cell–mediated disorders, such as solid organ rejection in cardiac, lung and hepatic transplantation, due to its immunotolerogenic effect. In addition, some data suggest that ECP might also have an immunogenic effect, generating an immune response against infections.

Methods

Herein we present a single-center case series of 13 patients with refractory histological-diagnosed BKVAN, where ECP was used after the failure of standard therapy. The cohort had a median age of 51 years (interquartile range 42–59), with 46% considered low immunological risk (cPRA 0%) and 54% high risk (cPRA >50%). ECP was initiated a median of 21.3 weeks (5.9–49.1) after BKVAN diagnosis, with patients receiving a median of 11 sessions (10–20).

Results

After starting ECP, serum BK viral load significantly decreased by 55.3%, 95.9%, 99.7% and 99.9% at 3, 6, 12 and 18 months after ECP, respectively, while kidney function slowly decreased but at a lower rate than the historical group not treated with ECP, and no adverse events were observed. Despite the reduction in immunosuppression, only one patient experienced graft rejection during follow-up, with no major impact on graft function.

Conclusion

These findings indicate that ECP may provide potential therapeutic benefits for BKVAN and could warrant further investigation in the context of kidney transplantation.

Schlagwörter

Stichwörter der Autor:innen

BK virusextracorporeal photopheresisimmunogenicityimmunological tolerancekidney transplantation

Autor:innen und Institutionen

  • Department of Nephrology and Kidney Transplantation, Hospital Clínic Barcelona, Catalonia, Spain.
  • Laboratori Experimental de Nefrologia I Transplantament Renal (LENIT), Fundació de Recerca Clínic Barcelona - Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS), Madrid, Spain.
  • Department of Medicine, Faculty of Medicine and Health Sciences, University of Barcelona, Barcelona, Spain.
  • Department of Pathology, Hospital Clínic Barcelona, Catalonia, Spain.
  • Apheresis Unit, Department of Hemotherapy and Hemostasis, Hospital Clínic Barcelona, Catalonia, Spain.

ORCID-Profile: Víctor J Escudero-Saiz, Marc Xipell, Ángela González, Diana Rodríguez-Espinosa, Carolt Arana, Pedro Ventura-Aguiar, Jordi Rovira, Joan Cid, Miquel Lozano

Zitieren

APA

Escudero-Saiz, V. J., Xipell, M., González, Á., Rodríguez-Espinosa, D., Cacho, J., Arana, C., Piñeiro, G. J., Ventura-Aguiar, P., Rovira, J., Larque, A. B., Charry, P., Cid, J., Oppenheimer, F., Bodro, M., Lozano, M., & Diekmann, F. (2025). Extracorporeal photopheresis for refractory BK virus–associated nephropathy in kidney transplantation. Clinical Kidney Journal, 18(12). https://doi.org/10.1093/ckj/sfaf250

Vancouver

Escudero-Saiz VJ, Xipell M, González Á, Rodríguez-Espinosa D, Cacho J, Arana C, et al. Extracorporeal photopheresis for refractory BK virus–associated nephropathy in kidney transplantation. Clinical Kidney Journal. 2025;18(12). doi:10.1093/ckj/sfaf250

BibTeX
@article{EscuderoSaiz2025,
  author = {Escudero-Saiz, Víctor J and Xipell, Marc and González, Ángela and Rodríguez-Espinosa, Diana and Cacho, Judit and Arana, Carolt and Piñeiro, Gastón J and Ventura-Aguiar, Pedro and Rovira, Jordi and Larque, Ana B and Charry, Paola and Cid, Joan and Oppenheimer, Federico and Bodro, Marta and Lozano, Miquel and Diekmann, Fritz},
  title = {Extracorporeal photopheresis for refractory BK virus–associated nephropathy in kidney transplantation},
  journal = {Clinical Kidney Journal},
  year = {2025},
  volume = {18},
  number = {12},
  doi = {10.1093/ckj/sfaf250}
}
Kostenlos starten →